{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:59:48Z","timestamp":1792007988516,"version":"4.4.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Contracept Reprod Med"],"DOI":"10.1186\/s40834-025-00399-8","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:07:09Z","timestamp":1759234029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of abnormal bleeding in etonogestrel-releasing implant users: quo vadis? An exploratory study on the attitudes of a cohort of Italian gynaecologists and review of the literature"],"prefix":"10.1186","volume":"10","author":[{"given":"Arianna","family":"Siconolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Azzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Seracchioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Meriggiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"1","key":"399_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.contraception.2017.10.003","volume":"97","author":"ML Kavanaugh","year":"2018","unstructured":"Kavanaugh ML, Jerman J. Contraceptive method use in the united states: trends and characteristics between 2008, 2012 and 2014. Contraception. 2018;97(1):14\u201321.","journal-title":"Contraception"},{"key":"399_CR2","doi-asserted-by":"crossref","unstructured":"Winner B, Buckel C, Secura GM. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012.2012;366(21):1998\u20132007.doi:10.1056\/NEJMoa1110855","DOI":"10.1056\/NEJMoa1110855"},{"issue":"3","key":"399_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/ajo.13319","volume":"61","author":"KI Black","year":"2021","unstructured":"Black KI, McGeechan K, Watson CJ, Lucke J, Taft A, McNamee K, et al. Women\u2019s satisfaction with and ongoing use of hormonal long-acting methods compared to the oral contraceptive pill: findings from an Australian general practice cluster randomised trial (ACCORd). Aust N Z J Obstet Gynaecol. 2021;61(3):448\u201353.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"399_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0010-7824(90)90094-C","volume":"42","author":"S D\u013aaz","year":"1990","unstructured":"D\u013aaz S, Croxatto HB, Pavez M, Belhadj H, Stern J, Sivin I. Clinical assessment of treatments for prolonged bleeding in users of NorplantR implants. Contraception. 1990;42(1):97\u2013109.","journal-title":"Contraception"},{"issue":"sup2","key":"399_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/14730782.2000.12288981","volume":"5","author":"HJTC Bennink","year":"2000","unstructured":"Bennink HJTC. The pharmacokinetics and pharmacodynamics of Implanon\u00ae, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000;5(sup2):12\u201320.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"399_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0015-0282(98)00015-6","volume":"69","author":"L M\u00e4k\u00e4r\u00e4inen","year":"1998","unstructured":"M\u00e4k\u00e4r\u00e4inen L, Van Beek A, Tuomivaara L, Asplund B, Bennink HC. Ovarian function during the use of a single contraceptive implant: implanon compared with Norplant. Fertil Steril. 1998;69(4):714\u201321.","journal-title":"Fertil Steril"},{"key":"399_CR7","doi-asserted-by":"publisher","first-page":"109920","DOI":"10.1016\/j.contraception.2022.109920","volume":"120","author":"S Reed","year":"2023","unstructured":"Reed S, Minh TD, Lange JA, Koro C, Heinemann K. Pregnancy and pregnancy outcomes in a prospective cohort study: final results from the nexplanon observational risk assessment study (NORA). Contraception. 2023;120:109920.","journal-title":"Contraception"},{"key":"399_CR8","doi-asserted-by":"crossref","unstructured":"Davies GC, Feng LX, Newton JR. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception. 1993;47(3):251\u201369. doi:10.1016\/0010-7824(93)90079-6","DOI":"10.1016\/0010-7824(93)90042-6"},{"issue":"6","key":"399_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/13625187.2012.726663","volume":"17","author":"M Laban","year":"2012","unstructured":"Laban M, Abd Alhamid M, Ibrahim EA, Elyan A, Ibrahim A. Endometrial histopathology, ovarian changes and bleeding patterns among users of long-acting progestin-only contraceptives in Egypt. Eur J Contracept Reprod Health Care. 2012;17(6):451\u20137.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"399_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/humrep\/15.1.118","volume":"15","author":"R Beerthuizen","year":"2000","unstructured":"Beerthuizen R, Van Beek A, Massai R, M\u00e4k\u00e4r\u00e4inen L, Hout JI, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon\u00ae compared to a non-hormonal method of contraception. Hum Reprod. 2000;15(1):118\u201322.","journal-title":"Hum Reprod"},{"issue":"6","key":"399_CR11","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00404-015-3784-0","volume":"292","author":"W Modesto","year":"2015","unstructured":"Modesto W, Dal\u00b4Ava N, Monteiro I, Bahamondes L. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet. 2015;292(6):1387\u201391.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"399_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00404-018-4851-0","volume":"298","author":"A Sansone","year":"2018","unstructured":"Sansone A, De Rosa N, Giampaolino P, Guida M, Lagan\u00e0 AS, Di Carlo C. Effects of etonogestrel implant on quality of life, sexual function, and pelvic pain in women suffering from endometriosis: results from a multicenter, prospective, observational study. Arch Gynecol Obstet. 2018;298(4):731\u20136.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"399_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.fertnstert.2018.07.003","volume":"110","author":"N Carvalho","year":"2018","unstructured":"Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018;110(6):1129\u201336.","journal-title":"Fertil Steril"},{"key":"399_CR14","doi-asserted-by":"publisher","first-page":"1460578","DOI":"10.3389\/fmed.2025.1460578","volume":"12","author":"Y Li","year":"2025","unstructured":"Li Y, Li D, Feng T, Wang C. Clinical efficacy of etonogestrel implants on relieving dysmenorrhea in endometriosis and adenomyosis women for up to 3 years. Front Med. 2025;12:1460578.","journal-title":"Front Med"},{"key":"399_CR15","doi-asserted-by":"crossref","unstructured":"Jiao N, Wang J, Mu H, Qi Q. Long-term outcomes of Implanon in managing adenomyosis: a 3-year prospective study. Med Sci Monit. 2025 [cited 2025 Apr 13];31. Available from: https:\/\/www.medscimonit.com\/abstract\/index\/idArt\/945972","DOI":"10.12659\/MSM.945972"},{"issue":"2","key":"399_CR16","doi-asserted-by":"publisher","first-page":"hoac009","DOI":"10.1093\/hropen\/hoac009","volume":"2022","author":"CM Becker","year":"2022","unstructured":"Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009.","journal-title":"Hum Reprod Open"},{"key":"399_CR17","doi-asserted-by":"publisher","first-page":"1172793","DOI":"10.3389\/fmed.2024.1172793","volume":"11","author":"R Ruiz De Vi\u00f1aspre-Hern\u00e1ndez","year":"2024","unstructured":"Ruiz De Vi\u00f1aspre-Hern\u00e1ndez R, Garrido-Santamaria R, Urra-Mart\u00ednez R, S\u00e1enz-Cabredo P, Garrido-Rivas AE, Ju\u00e1rez-Vela R, et al. Early removal of the etonogestrel contraceptive implant in Spanish women: a prospective cohort study. Front Med. 2024;11:1172793.","journal-title":"Front Med"},{"issue":"1","key":"399_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.fertnstert.2016.02.036","volume":"106","author":"D Apter","year":"2016","unstructured":"Apter D, Briggs P, Tuppurainen M, Grunert J, Lukkari-Lax E, Rybowski S, et al. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril. 2016;106(1):151\u2013e1575.","journal-title":"Fertil Steril"},{"issue":"6","key":"399_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/01.AOG.0000435452.86108.59","volume":"122","author":"DS Grunloh","year":"2013","unstructured":"Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122(6):1214\u201321.","journal-title":"Obstet Gynecol"},{"issue":"sup1","key":"399_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13625180801959931","volume":"13","author":"D Mansour","year":"2008","unstructured":"Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon\u00ae on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(sup1):13\u201328.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"399_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ajog.2014.07.025","volume":"212","author":"JT Diedrich","year":"2015","unstructured":"Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1):50.e1-50.e8.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"399_CR22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00404-025-07943-6","volume":"311","author":"JA Oliveira","year":"2025","unstructured":"Oliveira JA, Neves GL, Pinhati MES, De Oliveira FR, Filho ALDS. Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis. Arch Gynecol Obstet. 2025;311(4):1173\u201380.","journal-title":"Arch Gynecol Obstet"},{"key":"399_CR23","doi-asserted-by":"crossref","unstructured":"Hines G, Wang C, Walker T, Jereen A, Quinones JN, Waxman A. Continuation rates of the etonogestrel implant and factors associated with early discontinuation. Cureus. 2023 [cited 2025 Apr 13]; Available from: https:\/\/www.cureus.com\/articles\/143330-continuation-rates-of-the-etonogestrel-implant-and-factors-associated-with-early-discontinuation","DOI":"10.7759\/cureus.36117"},{"issue":"3","key":"399_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1210\/jc.2007-1907","volume":"93","author":"BA Swiglo","year":"2008","unstructured":"Swiglo BA, Murad MH, Sch\u00fcnemann HJ, Kunz R, Vigersky RA, Guyatt GH, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93(3):666\u201373.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"399_CR25","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1210\/jc.2006-0724","volume":"91","author":"M Hickey","year":"2006","unstructured":"Hickey M, Krikun G, Kodaman P, Schatz F, Carati C, Lockwood CJ. Long-term progestin-only contraceptives result in reduced endometrial blood flow and oxidative stress. J Clin Endocrinol Metab. 2006;91(9):3633\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"399_CR26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/aogs.13688","volume":"98","author":"S Palacios","year":"2019","unstructured":"Palacios S, Colli E, Regidor P. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98(12):1549\u201357.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"399_CR27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/humrep\/14.4.976","volume":"14","author":"HB Croxatto","year":"1999","unstructured":"Croxatto HB. A multicentre efficacy and safety study of the single contraceptive implant implanon. Hum Reprod. 1999;14(4):976\u201381.","journal-title":"Hum Reprod"},{"issue":"7","key":"399_CR28","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.3390\/ijms21072625","volume":"21","author":"S Houshdaran","year":"2020","unstructured":"Houshdaran S, Chen JC, Vallv\u00e9-Juanico J, Balayan S, Vo KC, Smith-McCune K, et al. Progestins related to progesterone and testosterone elicit divergent human endometrial transcriptomes and biofunctions. Int J Mol Sci. 2020;21(7):2625.","journal-title":"Int J Mol Sci"},{"key":"399_CR29","doi-asserted-by":"crossref","unstructured":"Chaovisitsaree S, Piyamongkol W, Pongsatha S, Morakote N, Noium S, Soonthornlimsiri N. One year study of Implanon on the adverse events and discontinuation. Contraception. 2004;70(2):169\u201373. doi:10.1016\/j.contraception.2004.02.008","DOI":"10.1016\/j.contraception.2004.02.008"},{"issue":"3","key":"399_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijgo.2005.06.007","volume":"90","author":"JBO Flores","year":"2005","unstructured":"Flores JBO, Balderas ML, Bonilla MC, V\u00e1zquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynecol Obstet. 2005;90(3):228\u201333.","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"399_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/13625180701442228","volume":"12","author":"B Yildizbas","year":"2007","unstructured":"Yildizbas B, Sahin HG, Kolusari A, Zeteroglu S, Kamac\u0131 M. Side effects and acceptability of Implanon\u00ae: a pilot study conducted in Eastern Turkey. Eur J Contracept Reprod Health Care. 2007;12(3):248\u201352.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"399_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/13625187.2013.853034","volume":"19","author":"E Weisberg","year":"2014","unstructured":"Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care. 2014;19(1):5\u201314.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"6","key":"399_CR33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3109\/09513590.2015.1018163","volume":"31","author":"C Di Carlo","year":"2015","unstructured":"Di Carlo C, Guida M, De Rosa N, Sansone A, Gargano V, Cagnacci A, et al. Bleeding profile in users of an etonogestrel sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population. Gynecol Endocrinol. 2015;31(6):491\u20134.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"399_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/13625189809051409","volume":"3","author":"O Kiriwat","year":"1998","unstructured":"Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Coelingh Bennink HJT. A 4-year pilot study on the efficacy and safety of Implanon\u00ae, a single-rod hormonal contraceptive implant in healthy women in Thailand. Eur J Contracept Reprod Health Care. 1998;3(2):85\u201391.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"399_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.contraception.2019.05.017","volume":"100","author":"D Mansour","year":"2019","unstructured":"Mansour D, Fraser IS, Edelman A, Vieira CS, Kaunitz AM, Korver T, et al. Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use? Contraception. 2019;100(4):264\u20138.","journal-title":"Contraception"},{"key":"399_CR36","doi-asserted-by":"crossref","unstructured":"Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999;60(1):1\u20138. doi:10.1016\/S0010-7824(99)00056-1","DOI":"10.1016\/S0010-7824(99)00053-0"},{"issue":"4","key":"399_CR37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/AOG.0000000000003452","volume":"134","author":"A Lazorwitz","year":"2019","unstructured":"Lazorwitz A, Aquilante CL, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship between etonogestrel concentrations and bleeding patterns in contraceptive implant users. Obstet Gynecol. 2019;134(4):807\u201313.","journal-title":"Obstet Gynecol"},{"key":"399_CR38","doi-asserted-by":"publisher","first-page":"110413","DOI":"10.1016\/j.contraception.2024.110413","volume":"133","author":"D Tsevat","year":"2024","unstructured":"Tsevat D, Mercier R, Bernheimer C, Lin S, Schwartz B. Amenorrhea in adolescents using the etonogestrel contraceptive implant. Contraception. 2024;133:110413.","journal-title":"Contraception"},{"issue":"5","key":"399_CR39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.contraception.2015.01.008","volume":"91","author":"A Dinh","year":"2015","unstructured":"Dinh A, Sriprasert I, Williams AR, Archer DF. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. Contraception. 2015;91(5):360\u20137.","journal-title":"Contraception"},{"issue":"3","key":"399_CR40","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0002-9440(10)64258-7","volume":"161","author":"G Krikun","year":"2002","unstructured":"Krikun G, Critchley H, Schatz F, Wan L, Caze R, Baergen RN, et al. Abnormal uterine bleeding during progestin-only contraception may result from free radical-induced alterations in angiopoietin expression. Am J Pathol. 2002;161(3):979\u201386.","journal-title":"Am J Pathol"},{"issue":"4","key":"399_CR41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/humupd\/dmad004","volume":"29","author":"MA Middelkoop","year":"2023","unstructured":"Middelkoop MA, Don EE, Hehenkamp WJK, Polman NJ, Griffioen AW, Huirne JAF. Angiogenesis in abnormal uterine bleeding: a narrative review. Hum Reprod Update. 2023;29(4):457\u201385.","journal-title":"Hum Reprod Update"},{"key":"399_CR42","doi-asserted-by":"crossref","unstructured":"Lockwood CJ, Krikun G, Hausknecht VA, Papp C, Schatz F. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal**This work was supported in part by grants from the National Institutes of Health R29-HD29540\u201301A1 and HD-94\u201323 (to C.J.L.). Portions of this work were presented at the 44th Annual Meeting of the Society for Gynecologic Investigation. (, Lockwood CJ, Krikun G, Hausknecht V, Wang E-Y, Ziegler D, Schatz F. Effects of RU 486 on endometrial stromal cell matrix metalloproteinase and matrix metalloproteinase inhibitor expression. Proceedings of the 44th Annual Meeting of the Society of Gynecologic Investigation, San Diego, CA, 1997, Abstract 220. Endocrinology. 1998;139(11):4607\u201313.","DOI":"10.1210\/endo.139.11.6304"},{"key":"399_CR43","doi-asserted-by":"crossref","unstructured":"Galant C, Vekemans M, Lemoine P, Kokorine I, Twagirayezu P, Henriet P, et al. Temporal and spatial association of matrix metalloproteinases with focal endometrial breakdown and bleeding upon progestin-only contraception. J Clin Endocrinol Metab. 2000;85(12):4827\u201334.","DOI":"10.1210\/jc.85.12.4827"},{"issue":"1","key":"399_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0002-9440(10)63277-4","volume":"165","author":"C Galant","year":"2004","unstructured":"Galant C, Berli\u00e8re M, Dubois D, Verougstraete JC, Charles A, Lemoine P, et al. Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am J Pathol. 2004;165(1):83\u201394.","journal-title":"Am J Pathol"},{"issue":"6","key":"399_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.5603\/GP.a2017.0063","volume":"88","author":"B Grzechoci\u0144ska","year":"2017","unstructured":"Grzechoci\u0144ska B, D\u0105browski F, Cyganek A, Panek G, Wielgo\u015b M. The role of metalloproteinases in endometrial remodelling during menstrual cycle. Ginekol Pol. 2017;88(6):337\u201342.","journal-title":"Ginekol Pol"},{"issue":"6","key":"399_CR46","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/0002-9378(92)91397-S","volume":"166","author":"J Bringer","year":"1992","unstructured":"Bringer J, Norgestimate. A clinical overview of a new progestin. Am J Obstet Gynecol. 1992;166(6):1969\u201379.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"399_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/09513590310001651740","volume":"18","author":"S Prifti","year":"2004","unstructured":"Prifti S, Lelle I, Zhong G, Strowitzki T, Rabe T. Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin. Gynecol Endocrinol. 2004;18(1):23\u20137.","journal-title":"Gynecol Endocrinol"},{"issue":"9","key":"399_CR48","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1210\/jc.2001-011969","volume":"87","author":"CJ Lockwood","year":"2002","unstructured":"Lockwood CJ, Krikun G, Koo ABC, Kadner S, Schatz F. Differential effects of thrombin and hypoxia on endometrial stromal and glandular epithelial cell vascular endothelial growth factor expression. J Clin Endocrinol Metab. 2002;87(9):4280\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"399_CR49","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.contraception.2017.04.001","volume":"95","author":"JP Shapiro","year":"2017","unstructured":"Shapiro JP, Guzeloglu-Kayisli O, Kayisli UA, Semerci N, Huang SJ, Arlier S, et al. Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding. Contraception. 2017;95(6):592\u2013601.","journal-title":"Contraception"},{"issue":"3","key":"399_CR50","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1210\/jc.2003-030141","volume":"89","author":"CJ Lockwood","year":"2004","unstructured":"Lockwood CJ, Kumar P, Krikun G, Kadner S, Dubon P, Critchley H, et al. Effects of thrombin, hypoxia, and steroids on interleukin-8 expression in decidualized human endometrial stromal cells: implications for long-term progestin-only contraceptive-induced bleeding. J Clin Endocrinol Metab. 2004;89(3):1467\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"399_CR51","doi-asserted-by":"crossref","unstructured":"Guzeloglu Kayisli O, Kayisli UA, Basar M, Semerci N, Schatz F, Lockwood CJ. Progestins upregulate FKBP51 expression in human endometrial stromal cells to induce functional progesterone and glucocorticoid withdrawal: implications for contraceptive- associated abnormal uterine bleeding. Critchley HOD, editor. PLOS ONE. 2015;10(10):e0137855.","DOI":"10.1371\/journal.pone.0137855"},{"issue":"13","key":"399_CR52","doi-asserted-by":"publisher","first-page":"10532","DOI":"10.3390\/ijms241310532","volume":"24","author":"S Arlier","year":"2023","unstructured":"Arlier S, Kayisli UA, Semerci N, Ozmen A, Larsen K, Schatz F, et al. Enhanced ZBTB16 levels by progestin-only contraceptives induces decidualization and inflammation. Int J Mol Sci. 2023;24(13):10532.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"399_CR53","doi-asserted-by":"publisher","first-page":"11062","DOI":"10.1038\/s41598-024-61751-7","volume":"14","author":"FR Torelli","year":"2024","unstructured":"Torelli FR, Rodrigues-Peres RM, Monteiro I, Lopes-Cendes I, Bahamondes L, Juliato CRT. Gene expression associated with unfavorable vaginal bleeding in women using the etonogestrel subdermal contraceptive implant: a prospective study. Sci Rep. 2024;14(1):11062.","journal-title":"Sci Rep"},{"issue":"3","key":"399_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/jog.14195","volume":"46","author":"SN Upawi","year":"2020","unstructured":"Upawi SN, Ahmad MF, Abu MA, Ahmad S. Management of bleeding irregularities among etonogestrel implant users: is combined oral contraceptives pills or nonsteroidal anti-inflammatory drugs the better option? J Obstet Gynaecol Res. 2020;46(3):479\u201384.","journal-title":"J Obstet Gynaecol Res"},{"issue":"5","key":"399_CR55","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13625187.2016.1210122","volume":"21","author":"MY Hou","year":"2016","unstructured":"Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracept Reprod Health Care. 2016;21(5):361\u20136.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"3","key":"399_CR56","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/AOG.0000000000000974","volume":"126","author":"M Guiahi","year":"2015","unstructured":"Guiahi M, McBride M, Sheeder J, Teal S. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. Obstet Gynecol. 2015;126(3):508\u201313.","journal-title":"Obstet Gynecol"},{"issue":"suppl 3","key":"399_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/humrep\/15.suppl_3.30","volume":"15","author":"DR Grow","year":"2000","unstructured":"Grow DR, Reece MT. The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception. Hum Reprod. 2000;15(suppl 3):30\u20138.","journal-title":"Hum Reprod"},{"issue":"6","key":"399_CR58","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.ajpath.2012.02.026","volume":"180","author":"M Helmestam","year":"2012","unstructured":"Helmestam M, Andersson H, Stavreus-Evers A, Brittebo E, Olovsson M. Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells. Am J Pathol. 2012;180(6):2527\u201335.","journal-title":"Am J Pathol"},{"issue":"11","key":"399_CR59","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.18203\/2320-1770.ijrcog20194876","volume":"8","author":"AN Fetih","year":"2019","unstructured":"Fetih AN, Abbas AM, Kamel FA, El Nashar IH. Tamoxifen for treatment of abnormal uterine bleeding in etonogestrel implant users: a randomized clinical trial. Int J Reprod Contracept Obstet Gynecol. 2019;8(11):4462.","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"issue":"3","key":"399_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jpag.2021.11.001","volume":"35","author":"JC Friedman","year":"2022","unstructured":"Friedman JC, Buyers E, Laurin J, Hampanda K, Alaniz VI. Tamoxifen for the treatment of etonogestrel implant-associated bleeding in an adolescent gynecology practice. J Pediatr Adolesc Gynecol. 2022;35(3):341\u20135.","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"2","key":"399_CR61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/AOG.0000000000003896","volume":"136","author":"AB Edelman","year":"2020","unstructured":"Edelman AB, Kaneshiro B, Simmons KB, Hauschildt JL, Bond K, Boniface ER, et al. Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized controlled trial. Obstet Gynecol. 2020;136(2):323\u201332.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"399_CR62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.contraception.2016.10.001","volume":"95","author":"KB Simmons","year":"2017","unstructured":"Simmons KB, Edelman AB, Fu R, Jensen JT. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial. Contraception. 2017;95(2):198\u2013204.","journal-title":"Contraception"},{"issue":"4","key":"399_CR63","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1471-0528.1981.tb01009.x","volume":"88","author":"SK Smith","year":"1981","unstructured":"Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. BJOG Int J Obstet Gynaecol. 1981;88(4):434\u201342.","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"399_CR64","doi-asserted-by":"publisher","unstructured":"Abdel-Aleem H, d\u2019Arcangues C, Vogelsong KM, Gaffield ML, G\u00fclmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2013 [cited 2025 Apr 23]. p. CD003449.pub4. Available from: https:\/\/doi.org\/10.1002\/14651858.CD003449.pub4","DOI":"10.1002\/14651858.CD003449.pub4"},{"key":"399_CR65","unstructured":"Phaliwong P, Taneepanichskul S. The effect of mefenamic acid on controlling irregular uterine bleeding second to Implanon use. J Med Assoc Thai. 2004;87(Suppl 3):S64\u2013S68."},{"issue":"2","key":"399_CR66","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/REP-08-0076","volume":"136","author":"NB Morison","year":"2008","unstructured":"Morison NB, Kaitu\u2019u-Lino TJ, Fraser IS, Salamonsen LA. Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives. Reproduction. 2008;136(2):267\u201374.","journal-title":"Reproduction"},{"issue":"1","key":"399_CR67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.fertnstert.2006.05.076","volume":"87","author":"JK Jain","year":"2007","unstructured":"Jain JK, Li A, Yang W, Minoo P, Felix JC. Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Fertil Steril. 2007;87(1):8\u201323.","journal-title":"Fertil Steril"},{"issue":"1","key":"399_CR68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/humrep\/dei273","volume":"21","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Hickey M, Palmer D, O\u2019Connor V, Salamonsen LA, Findlay JK, et al. A pilot study to assess the effect of three short-term treatments on frequent and\/or prolonged bleeding compared to placebo in women using implanon. Hum Reprod. 2006;21(1):295\u2013302.","journal-title":"Hum Reprod"},{"issue":"8","key":"399_CR69","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/humrep\/dep081","volume":"24","author":"E Weisberg","year":"2009","unstructured":"Weisberg E, Hickey M, Palmer D, O\u2019Connor V, Salamonsen LA, Findlay JK, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in implanon users. Hum Reprod. 2009;24(8):1852\u201361.","journal-title":"Hum Reprod"},{"issue":"2","key":"399_CR70","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.rbmo.2018.04.040","volume":"37","author":"J Donnez","year":"2018","unstructured":"Donnez J, Courtoy GE, Donnez O, Dolmans MM. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Reprod Biomed Online. 2018;37(2):216\u201323.","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"399_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.52054\/FVVO.15.2.078","volume":"15","author":"I Lambrecht","year":"2023","unstructured":"Lambrecht I, Van Den Bosch T. The use of a short course of ulipristal acetate for acute abnormal uterine bleeding in women without uterine fibroids. Facts Views Vis ObGyn. 2023;15(2):99\u2013105.","journal-title":"Facts Views Vis ObGyn"},{"issue":"4","key":"399_CR72","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/AOG.0000000000002810","volume":"132","author":"RE Zigler","year":"2018","unstructured":"Zigler RE, Madden T, Ashby C, Wan L, McNicholas C. Ulipristal acetate for unscheduled bleeding in etonogestrel implant users: a randomized controlled trial. Obstet Gynecol. 2018;132(4):888\u201394.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"399_CR73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1874210600802010005","volume":"2","author":"M Soory","year":"2008","unstructured":"Soory M. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review. Open Dent J. 2008;2(1):5\u201312.","journal-title":"Open Dent J"},{"issue":"4","key":"399_CR74","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.contraception.2011.08.006","volume":"85","author":"B Kaneshiro","year":"2012","unstructured":"Kaneshiro B, Edelman A, Carlson NE, Nichols M, Forbes MM, Jensen J. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception. 2012;85(4):351\u20138.","journal-title":"Contraception"},{"key":"399_CR75","unstructured":"Casey PM, Long ME, Drozdowicz LB, Marnach ML, Weaver AL. Management of etonogestrel subdermal implant\u2013related bleeding. J Reprod Med. 2014 Jun;59(3):306\u201312."},{"issue":"6","key":"399_CR76","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jpag.2021.05.011","volume":"34","author":"S Green","year":"2021","unstructured":"Green S, Sheeder J, Richards M. The etonogestrel implant in adolescents: factors associated with removal for bothersome bleeding in the first year after insertion. J Pediatr Adolesc Gynecol. 2021;34(6):825\u201331.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"399_CR77","unstructured":"World Health Organization. Selected practice recommendations for contraceptive use. 3rd ed. Geneva: World Health Organization. 2016 [cited 2025 Apr 23]. 72 p. Available from: https:\/\/iris.who.int\/handle\/10665\/252267"},{"key":"399_CR78","doi-asserted-by":"crossref","unstructured":"Curtis KM, Nguyen AT, Tepper NK, Zapata LB, Snyder EM, Hatfield-Timajchy K et al. U.S. Selected practice recommendations for contraceptive use, 2024. 2024;73(3).","DOI":"10.15585\/mmwr.rr7303a1"},{"issue":"1","key":"399_CR79","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/01443615.2015.1024210","volume":"36","author":"N Agarwal","year":"2016","unstructured":"Agarwal N, Gupta M, Kriplani A, Bhatla N, Singh N. Comparison of combined hormonal vaginal ring with ultralow-dose combined oral contraceptive pills in the management of heavy menstrual bleeding: a pilot study. J Obstet Gynaecol. 2016;36(1):71\u20135.","journal-title":"J Obstet Gynaecol"},{"issue":"2","key":"399_CR80","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/humrep\/deh604","volume":"20","author":"K Oddsson","year":"2005","unstructured":"Oddsson K, Leifels-Fischer B, Wiel-Masson D, De Melo NR, Benedetto C, Verhoeven CHJ, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 \u00b5g ethinylestradiol and 150 \u00b5g levonorgestrel: a randomized trial. Hum Reprod. 2005;20(2):557\u201362.","journal-title":"Hum Reprod"},{"issue":"9","key":"399_CR81","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/humrep\/del162","volume":"21","author":"I Milsom","year":"2006","unstructured":"Milsom I. Effects on cycle control and bodyweight of the combined contraceptive ring, nuvaring, versus an oral contraceptive containing 30\u00a0g ethinyl estradiol and 3\u00a0mg drospirenone. Hum Reprod. 2006;21(9):2304\u201311.","journal-title":"Hum Reprod"},{"issue":"5","key":"399_CR82","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.contraception.2005.05.005","volume":"72","author":"J Bulten","year":"2005","unstructured":"Bulten J, Grefte J, Siebers B, Dieben T. The combined contraceptive vaginal ring (NuvaRing) and endometrial histology. Contraception. 2005;72(5):362\u20135.","journal-title":"Contraception"},{"issue":"6","key":"399_CR83","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.contraception.2019.07.145","volume":"100","author":"CS Vieira","year":"2019","unstructured":"Vieira CS, Fraser IS, Plagianos MG, Burke AE, Westhoff CL, Jensen J, et al. Bleeding profile associated with 1-year use of the segesterone acetate\/ethinyl estradiol contraceptive vaginal system: pooled analysis from phase 3 trials. Contraception. 2019;100(6):438\u201344.","journal-title":"Contraception"},{"key":"399_CR84","doi-asserted-by":"crossref","unstructured":"Sinthuchai N, Tapanwong C, Apirakviriya N, Pohthipornthawat S, Santibenchakul U, Jaisamrarn U. Effect of a single dose of a combination injectable contraceptive for treatment of bothersome uterine bleeding in contraceptive implant(s) users: a randomized double-blind placebo-controlled trial. Contraception. 2023;131:110354.","DOI":"10.1016\/j.contraception.2023.110354"},{"issue":"1","key":"399_CR85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13104-023-06304-3","volume":"16","author":"V Lombardi F\u00e4h","year":"2023","unstructured":"Lombardi F\u00e4h V, Catarino R, Castillo S, Badda M, Gezer-Dickschat S, Thieringer F, et al. Can a 3 months treatment with oral desogestrel prior to insertion of the etonogestrel-releasing contraceptive implant improve continuation rate at 1 year? A randomized trial. BMC Res Notes. 2023;16(1):35.","journal-title":"BMC Res Notes"},{"key":"399_CR86","doi-asserted-by":"crossref","unstructured":"Grandi G, Feliciello L, Sgandurra A, Pedrini V, Guariglia G, Ferrari V, et al. Tips and tricks for the management of contraceptive etonogestrel implant in clinical practice: an expert opinion. Eur J Contracept Reprod Health Care. 2025 Apr;30(2):78\u201386. doi:10.1080\/13625187.2024.2434846.","DOI":"10.1080\/13625187.2024.2434846"},{"issue":"3","key":"399_CR87","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.contraception.2010.08.001","volume":"83","author":"D Mansour","year":"2011","unstructured":"Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception. 2011;83(3):202\u201310.","journal-title":"Contraception"},{"issue":"11","key":"399_CR88","first-page":"1503","volume":"58","author":"SA Mir","year":"2022","unstructured":"Mir SA, Ara R, Amin F, Malik A, Hamid L, Ali T, et al. Evaluation of the safety and efficacy of ormeloxifene, a selective estrogen receptor modulator and medroxyprogesterone acetate in women with non-structural abnormal uterine bleeding: a randomized clinical trial. Med (Mex). 2022;58(11):1503.","journal-title":"Med (Mex)"},{"issue":"5","key":"399_CR89","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00404-013-2839-3","volume":"288","author":"A Goshtasebi","year":"2013","unstructured":"Goshtasebi A, Moukhah S, Gandevani SB. Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid. Arch Gynecol Obstet. 2013;288(5):1055\u201360.","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"399_CR90","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s001980200080","volume":"13","author":"Y Ishida","year":"2002","unstructured":"Ishida Y, Ishida Y, Heersche JNM. Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporos Int. 2002;13(8):601\u20135.","journal-title":"Osteoporos Int"},{"issue":"2","key":"399_CR91","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/bmjsrh-2020-200619","volume":"47","author":"E Huvinen","year":"2021","unstructured":"Huvinen E, Holopainen E, Heikinheimo O. Norethisterone and its acetate \u2013 what\u2019s so special about them? BMJ Sex Reprod Health. 2021;47(2):102\u20139.","journal-title":"BMJ Sex Reprod Health"},{"issue":"6","key":"399_CR92","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1471-0528.1998.tb10172.x","volume":"105","author":"GA Irvine","year":"1998","unstructured":"Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkil\u00e4 A, Walker JJ, Cameron IT. Randomised comparative trial of the intrauterine system and norethisterone levonor gestrel for treatment of idiopathic menorrhagia. BJOG Int J Obstet Gynaecol. 1998;105(6):592\u20138.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"5","key":"399_CR93","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000443393","volume":"81","author":"M Kiseli","year":"2016","unstructured":"Kiseli M, Kayikcioglu F, Evliyaoglu O, Haberal A. Comparison of therapeutic efficacies of norethisterone, tranexamic acid and levonorgestrel-releasing intrauterine system for the treatment of heavy menstrual bleeding: a randomized controlled study. Gynecol Obstet Invest. 2016;81(5):447\u201353.","journal-title":"Gynecol Obstet Invest"},{"issue":"2","key":"399_CR94","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejogrb.2011.04.025","volume":"158","author":"AH James","year":"2011","unstructured":"James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124\u201334.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"399_CR95","doi-asserted-by":"crossref","unstructured":"Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. ACOG Committee Opinion No. 557. Obstet Gynecol. 2013;121(4):891\u20136.","DOI":"10.1097\/01.AOG.0000428646.67925.9a"},{"issue":"12","key":"399_CR96","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.3390\/jcm11123389","volume":"11","author":"N Vilk Ayalon","year":"2022","unstructured":"Vilk Ayalon N, Segev L, Samson AO, Yagel S, Cohen SM, Green T, et al. Norethisterone reduces vaginal bleeding caused by progesterone-only birth control pills. J Clin Med. 2022;11(12):3389.","journal-title":"J Clin Med"},{"issue":"4","key":"399_CR97","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09513590.2022.2046729","volume":"38","author":"PA Regidor","year":"2022","unstructured":"Regidor PA, Palacios S, Colli E. Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4\u00a0mg over nine cycles compared to desogestrel 0.075\u00a0mg. Gynecol Endocrinol. 2022;38(4):333\u20138.","journal-title":"Gynecol Endocrinol"},{"key":"399_CR98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.thromres.2022.08.016","volume":"218","author":"RM Booyens","year":"2022","unstructured":"Booyens RM, Engelbrecht AM, Strauss L, Pretorius E. To clot, or not to clot: the dilemma of hormone treatment options for menopause. Thromb Res. 2022;218:99\u2013111.","journal-title":"Thromb Res"},{"key":"399_CR99","doi-asserted-by":"crossref","unstructured":"Affandi B, Korver T, Geurts TBP, Coelingh Bennink HJT. A pilot efficacy study with a single-rod contraceptive implant (Implanon\u00ae1) in 200 Indonesian women treated for \u2264 4 years. Contraception. 1999 Mar;59(3):167\u201374. doi:10.1016\/S0010-7824(99)00015-3.","DOI":"10.1016\/S0010-7824(99)00015-3"}],"container-title":["Contraception and Reproductive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-025-00399-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40834-025-00399-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-025-00399-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:06:10Z","timestamp":1759277170000},"score":1,"resource":{"primary":{"URL":"https:\/\/contraceptionmedicine.biomedcentral.com\/articles\/10.1186\/s40834-025-00399-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1186\/s40834-025-00399-8","relation":{},"ISSN":["2055-7426"],"issn-type":[{"value":"2055-7426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given that the survey was addressed only to practising gynaecologists, the local Ethics Committee (Comitato Etico Area Vasta Emilia Centro) waived its requirement for approval; all participants freely gave their consent to participate to the survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}